ARCHIMED Acquires FIM Medical

ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

October 28, 2025

Medical Devices

ARCHIMED Diagnostics (ARCHIMED’s diagnostics team) has acquired a 60% stake in Fremont-based ARK Diagnostics from Soulbrain Holdings in a transaction valuing ARK at $428 million. Soulbrain retains and reinvests in a 40% stake and the deal includes a joint-venture agreement to accelerate ARK’s product development and global expansion.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires 75% Stake in ActiGraph

May 18, 2020

Medical Devices

ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.

Micromed (ARCHIMED portfolio) Acquires OSG BVBA

October 10, 2019

Medical Devices

ARCHIMED portfolio company Micromed has acquired Belgium-based EEG and PSG software specialist OSG BVBA. The deal gives Micromed direct access to the Benelux market (OSG has ~230 clients and ~50% penetration in the Netherlands) and adds software and AI sleep-scoring capabilities to accelerate product development and global distribution.